Business Description
Acurx Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00510M1045
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 7.51 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -33.6 | |||||
3-Year EPS without NRI Growth Rate | -33.6 | |||||
3-Year FCF Growth Rate | -30.1 | |||||
3-Year Book Growth Rate | 141.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 64.62 | |||||
9-Day RSI | 54.87 | |||||
14-Day RSI | 48.39 | |||||
6-1 Month Momentum % | -55.93 | |||||
12-1 Month Momentum % | -30.9 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.53 | |||||
Quick Ratio | 2.53 | |||||
Cash Ratio | 2.46 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.9 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -61.1 | |||||
ROA % | -178.37 | |||||
ROIC % | -4795.39 | |||||
ROCE % | -265.59 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.52 | |||||
Price-to-Tangible-Book | 0.52 | |||||
EV-to-EBIT | -1.67 | |||||
EV-to-EBITDA | -1.67 | |||||
EV-to-FCF | -2.48 | |||||
Price-to-Net-Current-Asset-Value | 6.47 | |||||
Price-to-Net-Cash | 6.68 | |||||
Earnings Yield (Greenblatt) % | -59.88 | |||||
FCF Yield % | -30.05 |